CStone Pharmaceuticals
CStone Pharmaceuticals, a biopharmaceutical company, researches and develops anti-cancer therapies to address the unmet medical needs of cancer patients in Mainland China and internationally. The company offers CEJEMLY (sugemalimab), a monoclonal antibody against programmed death (PD) ligand 1 for the treatment of non-small cell lung cancer (NSCLC), gastric adenocarcinoma/gastroesophageal junctio… Read more
Market Cap & Net Worth: CStone Pharmaceuticals (CSPHF)
CStone Pharmaceuticals (PINK:CSPHF) has a market capitalization of $756.85 Million ($756.85 Million) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #10303 globally and #4801 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying CStone Pharmaceuticals's stock price $0.52 by its total outstanding shares 1461101875 (1.46 Billion).
CStone Pharmaceuticals Market Cap History: 2020 to 2025
CStone Pharmaceuticals's market capitalization history from 2020 to 2025. Data shows change from $1.65 Billion to $756.85 Million (-15.24% CAGR).
CStone Pharmaceuticals Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how CStone Pharmaceuticals's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.81x
CStone Pharmaceuticals's market cap is 0.81 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $1.65 Billion | $1.04 Billion | -$1.22 Billion | 1.59x | N/A |
| 2021 | $1.81 Billion | $243.72 Million | -$1.92 Billion | 7.43x | N/A |
| 2022 | $863.51 Million | $481.36 Million | -$902.68 Million | 1.79x | N/A |
| 2023 | $469.01 Million | $463.84 Million | -$367.23 Million | 1.01x | N/A |
| 2024 | $330.21 Million | $407.20 Million | -$91.21 Million | 0.81x | N/A |
Competitor Companies of CSPHF by Market Capitalization
Companies near CStone Pharmaceuticals in the global market cap rankings as of March 18, 2026.
Key companies related to CStone Pharmaceuticals by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
CStone Pharmaceuticals Historical Marketcap From 2020 to 2025
Between 2020 and today, CStone Pharmaceuticals's market cap moved from $1.65 Billion to $ 756.85 Million, with a yearly change of -15.24%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $756.85 Million | +129.20% |
| 2024 | $330.21 Million | -29.60% |
| 2023 | $469.01 Million | -45.69% |
| 2022 | $863.51 Million | -52.34% |
| 2021 | $1.81 Billion | +9.73% |
| 2020 | $1.65 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of CStone Pharmaceuticals was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $756.85 Million USD |
| MoneyControl | $756.85 Million USD |
| MarketWatch | $756.85 Million USD |
| marketcap.company | $756.85 Million USD |
| Reuters | $756.85 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.